dichlororibofuranosylbenzimidazole has been researched along with Leukemia in 1 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Turinetto, V | 1 |
| Porcedda, P | 1 |
| Orlando, L | 1 |
| De Marchi, M | 1 |
| Amoroso, A | 1 |
| Giachino, C | 1 |
1 other study available for dichlororibofuranosylbenzimidazole and Leukemia
| Article | Year |
|---|---|
The cyclin-dependent kinase inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole induces nongenotoxic, DNA replication-independent apoptosis of normal and leukemic cells, regardless of their p53 status.
Topics: Apoptosis; Cell Line, Tumor; Cells, Cultured; Cyclin-Dependent Kinases; Dichlororibofuranosylbenzimi | 2009 |